Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

49.16 +0.12 (+0.24%)

Streaming Delayed Price Updated: 9:33 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9

...

43 44 Next >

GSK Lifts Outlook As Specialty Medicines, Vaccines Fuel Growth ↗

July 30, 2025

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

Via Benzinga

GSK Expects Full-Year Earnings At Top End Of Guidance: CEO Says ‘Confident In Our Long-Term Outlooks’ ↗

July 30, 2025

GSK now expects turnover growth to be toward the top end of 3% to 5% and core earnings per share growth to be closer to 8% at constant exchange rate.

Via Stocktwits

Topics Artificial Intelligence World Trade

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK

July 28, 2025

From Pomerantz LLP

Via GlobeNewswire

After Merck, Chinese Biotech Hengrui Pharma Collaborates With GSK In Worth $12 Billion Pact ↗

July 28, 2025

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 billion.

Via Benzinga

US FDA Reviewers Highlight Safety Concerns With GSK’s Investigational Cancer Drug: Retail’s On The Fence ↗

July 15, 2025

Via Stocktwits

Price Over Earnings Overview: GSK ↗

July 02, 2025

Via Benzinga

GSK's Blood Cancer Drug Review Extended As FDA Seeks More Data ↗

July 24, 2025

FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.

Via Benzinga

GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults

July 24, 2025

From GSK plc

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK

July 23, 2025

From Pomerantz LLP

Via GlobeNewswire

GSK's Blood Cancer Drug Faces US Setback Due To FDA Panel's Eye Safety Warning ↗

July 18, 2025

FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of July 23 PDUFA decision.

Via Benzinga

Dow Futures Edge Higher As Strong Earnings Boost Investor Confidence: AXP, NFLX, IBKR, GSK Among Stocks To Watch ↗

July 18, 2025

While Dow Jones futures were up 0.07% at the time of writing, the S&P 500 futures were up 0.03%.

Via Stocktwits

Topics ETFs Economy Government

GSK’s Blenrep Underwhelms FDA Panel Over Dose Risk-Benefit Balance In Myeloma; Retail Traders Stay Optimistic ↗

July 18, 2025

Despite the setback, GSK defended the drug’s potential, citing strong results from DREAMM trials.

Via Stocktwits

US FDA Approves GSK’s SHINGRIX in a Prefilled Syringe Presentation

July 17, 2025

From GSK plc

Via Business Wire

GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults ↗

July 15, 2025

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.

Via Benzinga

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? ↗

July 14, 2025

BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating.

Via Benzinga

GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance ↗

July 14, 2025

A decision by the FDA on the new submission is expected in the first half of 2026.

Via Stocktwits

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony ↗

July 11, 2025

Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal standards by the trial judge.

Via Benzinga

Topics Lawsuit

GSK Stock Gains As Flu Vaccine Rollout Begins And US Recovers From Most Severe Season In 15 Years ↗

July 10, 2025

Fluarix and Flulaval are being shipped in single-dose, 0.5 mL pre-filled syringes and are not recommended for individuals with severe allergies to vaccine components or a history of Guillain-Barré...

Via Stocktwits

Topics Death Lawsuit

GSK begins shipping influenza vaccine doses for the 2025-26 flu season

July 10, 2025

From GSK plc

Via Business Wire

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma ↗

July 08, 2025

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Via Stocktwits

CDC Greenlights Vaccines From Pfizer, Moderna, GSK Amid Shakeup Of Advisory Panel ↗

July 02, 2025

The agency expanded its RSV and meningococcal vaccine guidance to cover younger age groups and new formulations.

Via Stocktwits

Topics Government

Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons ↗

July 02, 2025

Via Benzinga

Ex-Pfizer Exec Pulled Into House Probe Over Alleged COVID Vaccine Delay Through 2020 Election ↗

June 30, 2025

The committee cited remarks allegedly made by Philip Dormitzer at GSK, claiming that Pfizer’s top R&D leaders delayed clinical trial progress to avoid releasing results before the 2020 election.

Via Stocktwits

Topics Government Law Enforcement

GSK Rebranded Flovent Asthma Inahler For Children To Avoid $367 Million Medicaid Rebate, Senator Hassan Accuses ↗

June 27, 2025

Senator Maggie Hassan is investigating GSK's discontinuation of Flovent HFA, citing increased hospitalizations, higher drug costs, and lost Medicaid rebates.

Via Benzinga

Why This Looming Supreme Court Decision Could Rattle Gilead Sciences ↗

June 27, 2025

The U.S. Supreme Court could make a decision Friday that would rattly Gilead Sciences' newest HIV prevention drug.

Via Investor's Business Daily

FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis

June 24, 2025

From GSK plc

Via Business Wire

AppLovin, First Solar And Li Auto Are Among Top 10 Large Cap Losers Last Week (June 16-20): Are The Others In Your Portfolio? ↗

June 22, 2025

Top 10 worst performing large-cap stocks last week: APP, FSLR, JHX, ONC, GSK, ACN, ANET, LI, CPAY, MA. Reasons include short-sell report, tax bill, and market selloff.

Via Benzinga

How KalVista Pharma Is Taking On A Rare But Deadly Disease ↗

June 20, 2025

The company is working on the first new on-demand treatment for hereditary angioedema in 11 years.

Via Investor's Business Daily

FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag ↗

June 20, 2025

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

43 44 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.